Toxicological Pathway Alterations Driven by Cervical microRNAs (miR-21, miR-155, miR-9) in Persistent High-Risk HPV Infection
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
29 December 2025
,
Page 1-12
https://doi.org/10.22037/ijmtfm.v16.51848
Abstract
Background: Persistent high-risk human papillomavirus (HR-HPV) infection is necessary for cervical carcinogenesis, yet most infections regress. Host microRNAs (miRNAs) that regulate cellular stress responses may help discriminate persistent from transient infection. In this study, we evaluated cervical expression of miR-21, miR-155, and miR-9 in relation to oxidative stress, DNA damage, apoptosis, and inflammatory signaling in HR-HPV persistence.
Methods: Cervical samples from 60 women referred to private laboratories in Tehran, the capital of Iran (2023-2024), were classified as persistent HR-HPV (qPCR-positive at baseline and 9 months), transient HR-HPV (positive at baseline and subsequently cleared), or HPV-negative controls with normal cytology. HPV DNA was monitored seasonally by qPCR; E6/E7 mRNA was assessed using the Aptima assay. miR-21, miR-155, and miR-9 were quantified using stem-loop RT-qPCR with normalization to U6 snRNA; relative expression was calculated by ΔΔCt. Group comparisons were performed using t-tests/ANOVA with Bonferroni correction (p<0.05).
Results: miR-21 and miR-155 were significantly elevated in persistent infection versus transient infection and controls (p<0.01). E6/E7 mRNA was detected in all persistent cases. In the transient group, 13/17 (76.5%) were E6/E7 mRNA-negative, whereas 4/17 (23.5%) were mRNA-positive at any time point. miR-21 and miR-155 correlated with E6/E7 mRNA positivity (r=0.74 and r=0.71; p<0.01). Over 12 months, miR-21 and miR-155 increased progressively in persistent infections (both p < 0.01), whereas they remained largely stable in the transient and control groups. miR-9 showed greater intra-group variability, fluctuating without a consistent trajectory and being lower than controls at multiple time points (p<0.05). Low-grade cytological abnormalities (inflammation/CIN1) were more frequent in persistent infections (p<0.05), with no HSIL observed.
Conclusions: HR-HPV persistence is associated with sustained upregulation of miR-21 and miR-155 and a heterogeneous, often reduced miR-9 pattern. This profile is biologically consistent with HPV-related molecular toxicity, including impaired apoptotic checkpoints, pro-inflammatory signaling, and potential facilitation of oxidative DNA damage accumulation. These miRNAs warrant further validation as early biomarkers of persistence and as indicators of stress-pathway remodeling during HPV-driven cervical transformation.
- Persistent HPV, microRNAs, miR-21, miR-155, miR-9, Cervical Cancer Precursors
How to Cite
References
[1] Aghamiri S, Talaei S, Roshanzamiri S, Zandsalimi F, Fazeli E, Aliyu M, et al. Delivery of genome editing tools: a promising strategy for HPV-related cervical malignancy therapy. Expert Opin Drug Deliv. 2020;17(6):753–66. [DOI: 10.1080/17425247.2020.1758226]
[2] Fazeli M, Soleimanjahi H, Dadashzadeh S. Further stimulation of cellular immune responses through association of HPV-16 E6, E7 and L1 genes in order to produce more effective therapeutic DNA vaccines in cervical cancer model. Iran J Cancer Prev. 2015;8(1):18–26. [DOI: 10.17795/ijcp-18]
[3] Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16(10):2389–2402. [DOI: 10.1080/21645515.2020.1786966]
[4] Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. 2006;(3):CD005037. [DOI: 10.1002/14651858.CD005037.pub2]
[5] Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–62. [DOI: 10.1038/nrd4663]
[6] Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res. 2012;18(4):771–81. [DOI: 10.1007/s12253-012-9539-9]
[7] Maroun J, Muñoz-Alía M, Ammayappan A, Schulze A, Peng KW, Russell SJ. Designing and building oncolytic viruses. Future Virol. 2017;12(4):193–213. [DOI: 10.2217/fvl-2016-0192]
[8] Baker AT, Aguirre-Hernández C, Halldén G, Parker AL. Designer oncolytic adenovirus: coming of age. Cancers (Basel). 2018;10(6):201. [DOI: 10.3390/cancers10060201]
[9] Liu TC, Halldén G, Wang Y, Brooks G, Francis J, Lemoine NR, et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther. 2004;9(6):786–803. [DOI: 10.1016/j.ymthe.2004.03.014]
[10] Ulasov IV, Borovjagin AV, Schroeder B, Baryshnikov AY. Oncolytic adenoviruses: a thorny path to glioma cure. Genes Dis. 2014;1(2):214–26. [DOI: 10.1016/j.gendis.2014.09.001]
[11] Chawra HS, Agarwal M, Mishra A, Chandel SS, Singh RP, Dubey G, et al. MicroRNA-21's role in PTEN suppression and PI3K/AKT activation: implications for cancer biology. Pathol Res Pract. 2024;254:155091. [DOI: 10.1016/j.prp.2024.155091]
[12] Alhassbalawi NK, Ebrahimabad MZ, Seyedhosseini FS, Bagheri Y, Abdollahi N, Nazari A, et al. Circulating miR-21 overexpression correlates with PDCD4 and IL-10 in systemic lupus erythematosus (SLE): a promising diagnostic and prognostic biomarker. Rep Biochem Mol Biol. 2023;12(2):220–7. [DOI: 10.52547/rbmb.12.2.220]
[13] Hu J, Huang S, Liu X, Zhang Y, Wei S, Hu X. miR-155: an important role in inflammation response. J Immunol Res. 2022;2022:7437281. [DOI: 10.1155/2022/7437281]
[14] Fang H, Shuang D, Yi Z, Sheng H, Liu Y. Up-regulated microRNA-155 expression is associated with poor prognosis in cervical cancer patients. Biomed Pharmacother. 2016;83:64–9. [DOI: 10.1016/j.biopha.2016.06.028]
[15] Mashima R. Physiological roles of miR-155. Immunology. 2015;145(3):323–33. [DOI: 10.1111/imm.12467]
[16] Sun J, Xiong J, Zhen Y, Chen ZL, Zhang H. P53 and PCNA is positively correlated with HPV infection in laryngeal epitheliopapillomatous lesions in patients with different ethnic backgrounds in Xinjiang. Asian Pac J Cancer Prev. 2012;13(11):5439–44. [DOI: 10.7314/apjcp.2012.13.11.5439]
[17] Park S, Eom K, Kim J, Bang H, Wang HY, Ahn S, et al. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer. 2017;17(1):658. [DOI: 10.1186/s12885-017-3642-5]
[18] Zhang C, Shu L, Kong AN. MicroRNAs: new players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways. Curr Pharmacol Rep. 2015;1(1):21–30. [DOI: 10.1007/s40495-015-0023-0]
[19] Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy EJ, et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-β2 in cervical keratinocytes. Cancer Res. 2000;60(15):4289–98. [DOI: 10.1002/1097-0142(20000715)89:2<428::aid-cncr15>3.0.co;2-6]
[20] Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A. 2009;106(13):5282–7. [DOI: 10.1073/pnas.0810909106]
[21] James MA, Lee JH, Klingelhutz AJ. Human papillomavirus type 16 E6 activates NF-κB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol. 2006;80(11):5301–7. [DOI: 10.1128/JVI.02397-05]
[22] Babion I, Jaspers A, van Splunter AP, van der Hoorn IA, Wilting SM, Steenbergen RD. miR-9-5p exerts a dual role in cervical cancer and targets transcription factor TWIST1. Cells. 2019;9(1):65. [DOI: 10.3390/cells9010065]
[23] Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Regulation of the transcription factor NF-κB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010;9:16. [DOI: 10.1186/1476-4598-9-16]
[24] Zamanian Azodi M, Rezaei Tavirani M, Rostami Nejad M, Vafaee R, Nazemalhosseini Mojarad E. Upregulation of miR-21 in HPV-positive cervical samples and its potential as a diagnostic biomarker in Iranian women. Asian Pac J Cancer Prev. 2015;16(14):5965–70. [DOI: 10.7314/apjcp.2015.16.14.5965
- Abstract Viewed: 31 times
- PDF Downloaded: 28 times